BioCentury | Aug 10, 2019
Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

...T cell lymphoma. Theratechnologies regains Egrifta rights Theratechnologies Inc. (TSX:TH) regained distribution rights to Egrifta tesamorelin...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Cardiovascular

...infarction (MI). Theratechnologies Inc., AOP Orphan Pharmaceuticals AG, BL&H Co. Ltd. and Sanofi market Egrifta tesamorelin...
BioCentury | Oct 5, 2015
Company News

Theratechnologies, BL&H deal

...Theratechnologies granted BL&H rights to develop and commercialize Egrifta tesamorelin in South Korea to treat HIV-associated...
...through named patient sales programs in the interim. Theratechnologies is responsible for manufacturing and supplying Egrifta...
BioCentury | Sep 14, 2015
Company News

Theratechnologies, AOP Orphan sales and marketing update

...Egrifta tesamorelin to treat lipodystrophy in HIV patients is now available in European countries as part...
...and Canada. Earlier this year, Theratechnologies granted AOP Orphan exclusive rights to develop and commercialize Egrifta...
BioCentury | Mar 16, 2015
Company News

Theratechnologies, AOP Orphan deal

...to develop and commercialize Egrifta tesamorelin in select countries within Europe. AOP Orphan will distribute Egrifta...
BioCentury | Sep 15, 2014
Company News

Theratechnologies, Merck KGaA sales and marketing update

...Theratechnologies said it sent a first shipment of 1 mg Egrifta tesamorelin to its U.S. distributor...
...treat excess abdominal fat in HIV patients with lipodystrophy. The company said new batches of Egrifta...
...U.S. rights to the product in May. In February, Theratechnologies said it expected inventory of Egrifta...
BioCentury | May 5, 2014
Company News

Actelion, Theratechnologies, Merck KGaA deal

...The companies completed the return of U.S. rights to Egrifta tesamorelin to Theratechnologies from Merck's EMD...
...HIV patients with lipodystrophy (see BioCentury, Dec. 23, 2013). Separately, Theratechnologies regained Canadian rights to Egrifta...
...provide financial compensation to any parties involved. On April 30, Theratechnologies said Health Canada approved Egrifta...
BioCentury | Feb 24, 2014
Company News

Theratechnologies sales and marketing update

...Theratechnologies said on Feb. 14 that it expects inventory of Egrifta tesamorelin to be depleted "in...
...due to manufacturing delays and production issues and that it would temporarily cease manufacture of Egrifta...
...when it would resume manufacturing. In December, Theratechnologies said it would regain U.S. rights to Egrifta...
BioCentury | Feb 24, 2014
Analyst Picks & Changes

Analyst picks & changes

...C$0.50 after Theratechnologies said on Feb. 14 that it expects inventory of lipodystrophy drug Egrifta tesamorelin...
...weeks" due to manufacturing delays and production issues. The company has temporarily ceased manufacture of Egrifta...
BioCentury | Dec 23, 2013
Company News

Theratechnologies, Merck KGaA deal

...Theratechnologies will regain U.S. rights to Egrifta tesamorelin from Merck's EMD Serono Inc. subsidiary for $20...
...amount is reached or until Jan. 1, 2024. Theratechnologies said that regaining U.S. rights to Egrifta...
...TSX:TH), Montreal, Quebec Merck KGaA (Xetra:MRK), Darmstadt, Germany Theratechnologies will regain U.S. rights to Egrifta tesamorelin...
Items per page:
1 - 10 of 176